NASDAQ:ATRS - Antares Pharma Stock Price, Forecast & News

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

Antares Pharma Inc (NASDAQ:ATRS) released its quarterly earnings data on Tuesday, November, 5th. The specialty pharmaceutical company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.02) by $0.03. The specialty pharmaceutical company had revenue of $34.31 million for the quarter, compared to analysts' expectations of $26.36 million. Antares Pharma had a negative return on equity of 1.40% and a negative net margin of 0.56%. View Antares Pharma's Earnings History.

Antares Pharma is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Antares Pharma.

3 analysts have issued 1 year target prices for Antares Pharma's stock. Their forecasts range from $1.99 to $5.65. On average, they anticipate Antares Pharma's stock price to reach $4.05 in the next year. This suggests that the stock has a possible downside of 13.7%. View Analyst Price Targets for Antares Pharma.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Antares Pharma.

Media stories about ATRS stock have been trending very negative recently, InfoTrie reports. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Antares Pharma earned a media sentiment score of -3.1 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Antares Pharma.

Antares Pharma saw a decline in short interest during the month of November. As of November 15th, there was short interest totalling 4,040,000 shares, a decline of 10.0% from the October 31st total of 4,490,000 shares. Based on an average daily trading volume, of 994,700 shares, the short-interest ratio is presently 4.1 days. Currently, 2.7% of the company's stock are short sold. View Antares Pharma's Current Options Chain.

Some companies that are related to Antares Pharma include Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), West Pharmaceutical Services (WST), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), STAAR Surgical (STAA), Merit Medical Systems (MMSI), Atrion (ATRI), Anika Therapeutics (ANIK), Cerus (CERS), OraSure Technologies (OSUR) and Meridian Bioscience (VIVO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Antares Pharma investors own include Ballard Power Systems (BLDP), Conatus Pharmaceuticals (CNAT), Hi-Crush Partners (HCLP), NVIDIA (NVDA), Prospect Capital (PSEC), Novavax (NVAX), Macquarie Infrastructure (MIC), Enviva Partners (EVA), Innovus Pharmaceuticals (INNV) and Advanced Micro Devices (AMD).

Antares Pharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (2.44%), Sargent Investment Group LLC (2.04%), State of New Jersey Common Pension Fund D (0.47%), Perkins Capital Management Inc. (0.19%), California Public Employees Retirement System (0.16%) and California State Teachers Retirement System (0.15%). Company insiders that own Antares Pharma stock include Jacques Gonella, Leonard S Jacob, Robert F Apple and Thomas J Garrity. View Institutional Ownership Trends for Antares Pharma.

ATRS stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Virtu Financial LLC, Perkins Capital Management Inc., Barclays PLC, SG Americas Securities LLC and Metropolitan Life Insurance Co NY. Company insiders that have sold Antares Pharma company stock in the last year include Jacques Gonella, Leonard S Jacob, Robert F Apple and Thomas J Garrity. View Insider Buying and Selling for Antares Pharma.

ATRS stock was bought by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Sargent Investment Group LLC, Monarch Partners Asset Management LLC, California Public Employees Retirement System, Russell Investments Group Ltd., Squarepoint Ops LLC, Cadence Capital Management LLC and CWM LLC. View Insider Buying and Selling for Antares Pharma.

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ATRS stock can currently be purchased for approximately $4.69.

Antares Pharma has a market capitalization of $765.55 million and generates $63.55 million in revenue each year. The specialty pharmaceutical company earns $-6,510,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. Antares Pharma employs 165 workers across the globe.View Additional Information About Antares Pharma.

The official website for Antares Pharma is http://www.antarespharma.com/.

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]